| Entry |
|
|---|
| Name |
Phenytoin (JP17/USP/INN);
Dilantin (TN) |
|---|
| Product |
|
|---|
| Generic |
PHENYTOIN (ATLANTIC BIOLOGICALS CORP.), PHENYTOIN (American Health Packaging), PHENYTOIN (American Health Packaging), PHENYTOIN INFATABS (Greenstone LLC), PHENYTOIN (Greenstone LLC), PHENYTOIN (Major Pharmaceuticals), PHENYTOIN (Morton Grove Pharmaceuticals), PHENYTOIN (Mylan Pharmaceuticals), PHENYTOIN INFATABS (NCS HealthCare of KY), DILANTIN INFATABS (Parke-Davis Div of Pfizer), PHENYTOIN (Pharmaceutical Associates), PHENYTOIN (REMEDYREPACK), PHENYTOIN (REMEDYREPACK), PHENYTOIN (Taro Pharmaceuticals U.S.A.), PHENYTOIN (Taro Pharmaceuticals U.S.A.), PHENYTOIN (VistaPharm), PHENYTOIN (VistaPharm) |
|---|
| Formula |
C15H12N2O2
|
|---|
| Exact mass |
252.0899
|
|---|
| Mol weight |
252.268
|
|---|
| Structure |
|
|---|
| Simcomp |
|
|---|
| Class |
Neuropsychiatric agent
DG02031 Hydantoin antiepileptics
Metabolizing enzyme substrate
DG01642 CYP2C9 substrate
DG01639 CYP2C19 substrate
Metabolizing enzyme inducer
DG02891 CYP2B6 inducer
DG02853 CYP3A inducer
Transporter inducer
DG01893 ABCB1 (P-GP) inducer
|
|---|
| Remark |
| Therapeutic category: | 1132 |
| Product (DG00846): | D00512<JP/US> D02103<JP/US> |
| Product (mixture): | D07583<JP> |
|
|---|
| Efficacy |
Antiepileptic |
|---|
| Comment |
Hydantoin derivative
|
|---|
| Target |
|
|---|
| Pathway |
|
|---|
| Metabolism |
Enzyme: CYP2C9 [HSA: 1559]; CYP2C19 [HSA: 1557]
|
|---|
| Interaction |
CYP induction: CYP3A [HSA: 1576 1577 1551], CYP2B6 [HSA: 1555]
Transporter induction: ABCB1 [HSA: 5243]
|
|---|
| Structure map |
|
|---|
| Other map |
|
|---|
| Brite |
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
N NERVOUS SYSTEM
N03 ANTIEPILEPTICS
N03A ANTIEPILEPTICS
N03AB Hydantoin derivatives
N03AB02 Phenytoin
D00512 Phenytoin (JP17/USP/INN) <JP/US>
USP drug classification [BR:br08302]
Anticonvulsants
Sodium Channel Agents
Phenytoin
D00512 Phenytoin (JP17/USP/INN)
Therapeutic category of drugs in Japan [BR:br08301]
1 Agents affecting nervous system and sensory organs
11 Agents affecting central nervous system
113 Antiepileptics
1132 Hydantoins
D00512 Phenytoin (JP17/USP/INN)
Target-based classification of drugs [BR:br08310]
Ion channels
Voltage-gated ion channels
Sodium channels
SCN1A
D00512 Phenytoin (JP17/USP/INN) <JP/US>
SCN2A
D00512 Phenytoin (JP17/USP/INN) <JP/US>
SCN3A
D00512 Phenytoin (JP17/USP/INN) <JP/US>
SCN4A
D00512 Phenytoin (JP17/USP/INN) <JP/US>
SCN5A
D00512 Phenytoin (JP17/USP/INN) <JP/US>
SCN8A
D00512 Phenytoin (JP17/USP/INN) <JP/US>
SCN9A
D00512 Phenytoin (JP17/USP/INN) <JP/US>
SCN10A
D00512 Phenytoin (JP17/USP/INN) <JP/US>
SCN11A
D00512 Phenytoin (JP17/USP/INN) <JP/US>
Drugs listed in the Japanese Pharmacopoeia [BR:br08311]
Chemicals
D00512 Phenytoin
D00512 Phenytoin tablets
D00512 Phenytoin powder
Drug metabolizing enzymes and transporters [br08309.html]
Drug metabolizing enzymes
D00512
Drug transporters
D00512
Pharmacogenomic biomarkers [br08341.html]
Polymorphisms and mutations affecting drug response
D00512
Prodrugs [br08324.html]
D00512
|
|---|
| Other DBs |
|
|---|
| KCF data |
ATOM 19
1 C1z C 21.1928 -17.0796
2 N1x N 21.6897 -15.8145
3 C2y C 20.5391 -14.9868
4 N2x N 19.3790 -15.7706
5 C5x C 19.8336 -17.0686
6 O1a O 20.5108 -13.5697
7 O5x O 19.0059 -18.2260
8 C8y C 22.5928 -17.0796
9 C8x C 23.2971 -18.2998
10 C8x C 24.6971 -18.2999
11 C8x C 25.3972 -17.0875
12 C8x C 24.6928 -15.8673
13 C8x C 23.2928 -15.8672
14 C8y C 21.1928 -18.4796
15 C8x C 19.9931 -19.1723
16 C8x C 19.9932 -20.5723
17 C8x C 21.2057 -21.2722
18 C8x C 22.4053 -20.5795
19 C8x C 22.4052 -19.1795
BOND 21
1 1 2 1
2 2 3 1
3 3 4 2
4 4 5 1
5 1 5 1
6 3 6 1
7 5 7 2
8 1 8 1
9 8 9 2
10 9 10 1
11 10 11 2
12 11 12 1
13 12 13 2
14 8 13 1
15 1 14 1
16 14 15 2
17 15 16 1
18 16 17 2
19 17 18 1
20 18 19 2
21 14 19 1
|
|---|
